BioNTech acquired CureVac for mRNA technology and entered a collaboration to co-develop BNT327.
4 reports, 3 independent
Updated Aug 28
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 4
- Repetition
- 25%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioNTech acquired CureVac for mRNA technology and entered a collaboration to co-develop BNT327.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- BioNTech included CureVac operations in its expenses.Sub-event
BioNTech acquires CureVac for mRNA tech and collaborates on BNT327.1 source
The two companies settled a patent dispute related to mRNA technology.1 source
The BNT327 clinical program collaboration between BioNTech and CureVac has advanced.1 source
Keep exploring
The entities involved
Coverage
Newest first; wire copies grouped- Insider MonkeyBioNTech SE (BNTX) Teams Up with BMS in $11B Cancer Deal We recently published 11 Best Cancer Stocks to Buy Right Now. BioNTech SE is one of them. BioNTech SE (NASDAQ:BNTX), a German biotechnology co
- Simply Wall St.BioNTech (BNTX) Settles mRNA Patent Dispute with CureVac for US$370 Million Recent developments have highlighted a major mRNA patent settlement involving BioNTech and CureVac, leading to a $370 milli
- GlobeNewswireBioNTech Announces Second Quarter 2025 Financial Results and Corporate Update Continued execution of BioNTech’s oncology strategy with focus on two pan-tumor programs including two announced transact
- Unknown outlet